1. Challenges in Individualizing Drug Dosage for Intensive Care Unit Patients: Is Augmented Renal Clearance What We Really Want to Know? Some Suggested Management Approaches and Clinical Software Tools

   • Roger Jelliffe

   Current Opinion 25 February 2016 Pages: 897 - 905

   

2. Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials

   • Vincent Madelain
   • Thi Huyen Tram Nguyen
   • France Mentré

   Review Article 21 January 2016 Pages: 907 - 923

   

3. Drug Interactions with Lithium: An Update

   • Patrick R. Finley

   Review Article 02 March 2016 Pages: 925 - 941

4. Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I–III Clinical Trials

   • Lei Diao
   • Yaming Hang
   • Jonathan Q. Tran

   Original Research Article 12 February 2016 Pages: 943 - 955

   

5. Development of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model to Predict the Impact of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics Represented by Receptor/Transporter Occupancy of Central Nervous System Drugs

   • Saeed Alqahtani
   • Amal Kaddoumi

   Original Research Article 25 February 2016 Pages: 957 - 969

   

6. A Single-Dose Crossover Pharmacokinetic Comparison Study of Oral, Rectal and Topical Quetiapine in Healthy Adults

   • Jonathan G. Leung
   • Sarah Nelson
   • Maria I. Lapid

   Original Research Article 12 February 2016 Pages: 971 - 976

   

7. Quantitative Prediction of Drug Interactions Caused by CYP1A2 Inhibitors and Inducers

   • Laurence Gabriel
   • Michel Tod
   • Sylvain Goutelle

   Original Research Article 02 March 2016 Pages: 977 - 990

   

8. Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients with Atrial Tachyarrhythmias

   • Joe-Elie Salem
   • Maria El-Aissaoui
   • Saik Urien

   Original Research Article 05 March 2016 Pages: 991 - 1002

   

9. Drug–Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers

   • Akshanth R. Polepally
   • Jennifer R. King
   • Rajeev M. Menon

   Original Research Article Open access 19 February 2016 Pages: 1003 - 1014

   

10. Revisiting Dosing Regimen Using Pharmacokinetic/Pharmacodynamic Mathematical Modeling: Densification and Intensification of Combination Cancer Therapy

    • Christophe Meille
    • Dominique Barbolosi
    • Athanassios Iliadis

    Original Research Article 05 March 2016 Pages: 1015 - 1025